Search results
Results from the WOW.Com Content Network
Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November ...
The COVID Moonshot is a collaborative open-science project started in March 2020 with the goal of developing an un-patented oral antiviral drug to treat SARS-CoV-2, the virus causing COVID-19. [1] [2] COVID Moonshot researchers are targeting the proteins needed to form functioning new viral proteins. [3]
COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic ...
[5] [93] [94] [95] One study from April 2020 found that people with COVID-19 and hypertension had lower all-cause mortality when on these medications. [96] Similar concerns were raised about non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen; these were likewise not borne out, and NSAIDs may both be used to relieve symptoms of ...
Two drug companies have developed antiviral pills to fight Covid-19. They both work by blocking enzymes that play a role in how the virus replicates in the body.
One antiviral strategy is to interfere with the ability of a virus to infiltrate a target cell. The virus must go through a sequence of steps to do this, beginning with binding to a specific " receptor " molecule on the surface of the host cell and ending with the virus "uncoating" inside the cell and releasing its contents.
Researchers at Boston’s Dana-Farber Cancer Institute are working on a drug that takes one of the virus’s most dangerous traits — its talent for mutation — and turns it back on itself.
The research that led to nirmatrelvir began in March 2020, when Pfizer formally launched a project at its Cambridge, Massachusetts site to develop antiviral drugs for treating COVID-19. [15] In July 2020, Pfizer chemists were able to synthesize nirmatrelvir for the first time. [15] In September 2020, Pfizer completed a pharmacokinetic study in ...